L'intérêt à découvert pour Alzamend Neuro donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Alzamend Neuro. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Alzamend Neuro (NASDAQ:ALZN) Stock, Rapport sur les intérêts à découvert

Alzamend Neuro

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Alzamend Neuro Inc

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Events

Market-Moving Exclusives

Markets

$BTC

$ETH

Tanya Solati, VP Of Business Development For Propy, Says Web3 Lacks User Friendliness And Usability, Says It's Frustrating For Many Users

Exclusives

Broadridge's Aviad Stein Says Web3 Is An 'Evolution' To What We Are Doing, Says It's Like Going Back To Web1, To The Beginning Of The Internet

Financial giants have made a conspicuous bearish move on Carvana. Our analysis of options history for Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) revealed 34 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 47% showed bearish tendencies. Out of all the trades we spotted, 16 were puts, with a value of $1,827,307, and 18 were calls, valued at $1,362,695.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $300.0 for Carvana over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Carvana's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Carvana's significant trades, within a strike price range of $15.0 to $300.0, over the past month.
<h3>Carvana Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732044648_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$32.35</td>
<td>$31.95</td>
<td>$32.35</td>
<td>$260.00</td>
<td>$342.8K</td>
<td align="right">207</td>
<td align="right">429</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$32.55</td>
<td>$32.15</td>
<td>$32.36</td>
<td>$260.00</td>
<td>$323.6K</td>
<td align="right">207</td>
<td align="right">681</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$32.6</td>
<td>$32.05</td>
<td>$32.33</td>
<td>$260.00</td>
<td>$323.3K</td>
<td align="right">207</td>
<td align="right">794</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$32.45</td>
<td>$32.35</td>
<td>$32.4</td>
<td>$260.00</td>
<td>$204.3K</td>
<td align="right">207</td>
<td align="right">492</td>
</tr>
<tr>
<td>CVNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$32.45</td>
<td>$32.35</td>
<td>$32.44</td>
<td>$260.00</td>
<td>$178.2K</td>
<td align="right">207</td>
<td align="right">548</td>
</tr>
</tbody>
</table>

<h3>About Carvana</h3>
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
Following our analysis of the options activities associated with Carvana, we pivot to a closer look at the company's own performance.
<h3>Where Is Carvana Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,025,270, the CVNA's price is up by 2.36%, now at $250.47. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 93 days.</li>
</ul>
<h3>Professional Analyst Ratings for Carvana</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $267.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a In-Line rating for Carvana, targeting a price of $190. 
&#x2A; An analyst from Needham persists with their Buy rating on Carvana, maintaining a target price of $300. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Carvana, maintaining a target price of $300. 
&#x2A; An analyst from JMP Securities persists with their Market Outperform rating on Carvana, maintaining a target price of $320. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Carvana, maintaining a target price of $225. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Carvana with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

CVNA

What the Options Market Tells Us About Carvana

Investors with a lot of money to spend have taken a bearish stance on Medical Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MPW, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Medical Properties Trust.
This isn't normal.
The overall sentiment of these big-money traders is split between 6% bullish and 75%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $1,537,381, and 5 are calls, for a total amount of $204,471.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $0.5 to $7.0 for Medical Properties Trust over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Medical Properties Trust's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Medical Properties Trust's substantial trades, within a strike price spectrum from $0.5 to $7.0 over the preceding 30 days.
<h3>Medical Properties Trust Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732044642_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.2</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$7.00</td>
<td>$320.0K</td>
<td>4.3K</td>
<td>1.4K</td>
</tr>
<tr>
<td>MPW</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$1.59</td>
<td>$1.34</td>
<td>$1.45</td>
<td>$5.50</td>
<td>$290.0K</td>
<td>13.5K</td>
<td>2.3K</td>
</tr>
<tr>
<td>MPW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.2</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$7.00</td>
<td>$224.9K</td>
<td>4.3K</td>
<td>5.9K</td>
</tr>
<tr>
<td>MPW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.2</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$7.00</td>
<td>$160.0K</td>
<td>4.3K</td>
<td>4.8K</td>
</tr>
<tr>
<td>MPW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.2</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$7.00</td>
<td>$160.0K</td>
<td>4.3K</td>
<td>4.3K</td>
</tr>
</tbody>
</table>

<h3>About Medical Properties Trust</h3>
Medical Properties Trust Inc is a healthcare facility REIT. The company operates one segment, which owns and leases healthcare facilities. The vast majority of Medical's revenue is generated in the United States, followed by Germany and the United Kingdom. It provides financing for a variety of facilities that require funds for acquisitions, sale-leasebacks, new developments, and expansion projects.
Having examined the options trading patterns of Medical Properties Trust, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Medical Properties Trust</h3>
<ul>
<li>With a trading volume of 6,182,287, the price of MPW is up by 1.43%, reaching $4.27.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 92 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Medical Properties Trust options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Medical Properties Trust Unusual Options Activity For November 19

1iO Founder, CEO Markus Kuhnert Says Web3 Is About Companies Owning Infrastructure; Says Data Is The Biggest Upcoming Challenge, Says 'We Need To Bring It Back To The People'

Investors with a lot of money to spend have taken a bearish stance on Oscar Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with OSCR, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for Oscar Health.
This isn't normal.
The overall sentiment of these big-money traders is split between 18% bullish and 72%, bearish.
Out of all of the options we uncovered, 10 are puts, for a total amount of $694,572, and there was 1 call, for a total amount of $38,464.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $17.5 to $20.0 for Oscar Health over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Oscar Health's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Oscar Health's whale trades within a strike price range from $17.5 to $20.0 in the last 30 days. 
<h3>Oscar Health Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732044636_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSCR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$20.00</td>
<td>$117.6K</td>
<td align="right">229</td>
<td>215</td>
</tr>
<tr>
<td>OSCR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$2.4</td>
<td>$2.25</td>
<td>$2.35</td>
<td>$19.00</td>
<td>$93.3K</td>
<td align="right">633</td>
<td>1.0K</td>
</tr>
<tr>
<td>OSCR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.45</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$19.00</td>
<td>$93.1K</td>
<td align="right">633</td>
<td>134</td>
</tr>
<tr>
<td>OSCR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.1</td>
<td>$20.00</td>
<td>$62.0K</td>
<td align="right">229</td>
<td>1.4K</td>
</tr>
<tr>
<td>OSCR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.1</td>
<td>$20.00</td>
<td>$62.0K</td>
<td align="right">229</td>
<td>1.1K</td>
</tr>
</tbody>
</table>

<h3>About Oscar Health</h3>
Oscar Health Inc is a health insurance company. The company provides various insurance plans for individuals, families, and employees. Also, the company provides virtual care, doctor support, scheduling appointments, and other related services. The company provides plans in the Medicare Advantage program to adults who are age 65 and older and eligible for traditional Medicare but who instead select coverage through a private market plan.
Following our analysis of the options activities associated with Oscar Health, we pivot to a closer look at the company's own performance.
<h3>Where Is Oscar Health Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 4,525,269, with OSCR's price up by 12.73%, positioned at $18.02.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 78 days.</li>
</ul>
<h3>Expert Opinions on Oscar Health</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $13.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities downgraded its action to Underperform with a price target of $13. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Oscar Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

OSCR

Looking At Oscar Health's Recent Unusual Options Activity

- Investor day 
&nbsp;https://www.qualcomm.com/company/events/investor-day

Guidance

QCOM

Qualcomm Sees Total Market Opportunity Of $900B By 2030

Aviad Stein, Global Head Of Strategy and Innovation At Broadridge Financial, Says Transition From Web2 To Web3 Is 'Painful,' But It Takes Leadership

WIIM

DNMR

Danimer Scientific shares are trading lower. The company reported Q3 financial results.

GOOG

GOOGL

Google's Richard Widmann Says Stripe's Acquisition Of Bridge Has 'Opened People's Eyes' On New Ways Of Moving Value Across The Chain

Richard Widmann, Head Of Strategy, Web3 For Google Cloud, Says Looking At Web3 'We're not just moving information, we're moving value'

The European Union's Markets in Crypto-Assets (MiCA) regulation is set for full implementation by December 2024, placing pressure on crypto exchanges and asset providers to meet stringent new standards. 
Ahead of her appearance at the upcoming <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets event</a>, Sandra Ro, CEO of Global Blockchain Business Council (GBBC), discussed the challenges facing European market players as they prepare for MiCA's requirements.
Reflecting on earlier compliance deadlines, Ro noted confusion led many exchanges to delist certain assets: "As we saw in the June 30 MiCA deadline for fiat-backed stablecoin compliance, there was confusion in the market, and most crypto exchanges decided to delist certain ‘non-compliant' stablecoins."
<h1 class="wp-block-heading">Travel Rule Compliance and Industry Uncertainty</h1>
With MiCA's travel rule set to take effect in December 2024, Ro pointed to ongoing concerns about how it will apply to crypto asset service providers (CASPs) across Europe. The rule will require CASPs to track information on crypto transactions for transparency. 
<figure class="wp-block-image size-full"><a href="https://benzinga.swoogo.com/digital-assets/6342807"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13234126/905735A6-57D3-4874-9AA1-75D037842DB3-1-12.gif" alt="" class="wp-image-646853" /></a></figure>
Ro cited Elsa Madrolle of VerifyVASP, who recently posted on LinkedIn that the European Banking Authority (EBA) proposed a "tolerance period of six months during which full travel rule functionality mishaps will be tolerated." However, according to Ro, the terms of this transition remain unclear, as some providers might be permitted to implement the rule gradually, while others may not receive the same leeway.
Madrolle's post further reveals a lack of consensus among regulators, particularly concerning whether CASPs will be allowed "grandfather" status or need immediate compliance by the end-of-year deadline. As Ro explained, interpretations of MiCA's provisions could vary widely, leaving questions about the enforcement scope.
<h1 class="wp-block-heading">Compliance and Potential Enforcement Challenges</h1>
Ro stressed that meeting MiCA's compliance standards will not be straightforward for many operators. "The practicality of implementation is often less straightforward than practitioners would like as specific details or concepts like being ‘grandfathered or not' are up for interpretation," she said. 
These challenges raise questions about how enforcement might unfold, especially if crypto exchanges and CASPs are labeled "non-compliant" for failing to meet MiCA's demands on time. As Europe's digital asset market adjusts to these incoming regulations, Ro's remarks suggest that the MiCA framework could reshape the landscape for well-established and newer entrants in the industry. 
For more of Madrolle's analysis on the topic, her LinkedIn post can be viewed here. Ro is expected to delve further into these issues at the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets</a> event as the industry prepares for upcoming regulatory developments in the European market.
<hr class="wp-block-separator has-alpha-channel-opacity" />
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field. <a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a> event in New York City on Nov. 19 will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.
Photo: Shutterstock

Global

Interview

As MiCA Compliance Deadline Approaches, Will European Crypto Exchanges Face Enforcement Risks?

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has unveiled its upcoming additions to Xbox Game Pass for the second half of November, featuring high-profile launches and exciting<a href="https://www.benzinga.com/general/gaming"> indie gems. </a>
Subscribers can look forward to a mix of blockbuster games, indie adventures, and in-game rewards, though a handful of titles will soon leave the service.
<h3 class="wp-block-heading">New Additions To Xbox Game Pass:</h3>
Here's a breakdown of the new titles arriving on Xbox Game Pass in late November, as <a href="https://news.xbox.com/en-us/2024/11/19/xbox-game-pass-november-2024-wave-2/">detailed</a> in an Xbox blog post:
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/42013601/phil-spencer-responds-to-this-is-an-xbox-criticism-were-in-the-middle-of-a-transition">Phil Spencer Responds To &#8216;This Is An Xbox&#8217; Criticism: &#8216;We&#8217;re In The Middle Of A Transition&#8217;</a>
<ul>
<li>Microsoft Flight Simulator 2024 (Cloud, PC, and Xbox Series X&#x7C;S) – Nov. 19: The latest iteration of this iconic series pushes realism and immersive gameplay to new heights. Available with Game Pass Ultimate and PC Game Pass.</li>
<li>Stalker 2: Heart of Chornobyl (Cloud, PC, and Xbox Series X&#x7C;S) – Nov. 20: The long-anticipated survival-horror shooter from GSC Game World finally launches. Ultimate and PC Game Pass subscribers can dive into this atmospheric journey.</li>
<li>Little Kitty, Big City (Console) – Nov. 20: A whimsical adventure now available to standard Game Pass subscribers.</li>
<li>PlateUp! (Console) – Nov. 20: A chaotic cooking simulator arrives for standard Game Pass users, blending fun and strategy.</li>
<li>Nine Sols (Cloud, PC, and Xbox Series X&#x7C;S) – Nov. 26: An artistic action-platformer with Sekiro-inspired combat. Exclusive to Ultimate and PC Game Pass.</li>
<li>Aliens: Dark Descent (Cloud, PC, and Xbox Series X&#x7C;S) – Nov. 27: Last year's well-received tactical title, based on the Aliens universe, comes to Ultimate and PC Game Pass.</li>
</ul>
<h3 class="wp-block-heading">Exclusive Rewards For Genshin Impact Players</h3>
With Genshin Impact launching on Xbox on Nov. 20, Game Pass Ultimate subscribers will receive an exclusive bundle of in-game rewards to kickstart their journey in the Hoyoverse RPG. Rewards include Intertwined Fates, Mora, and other resources.
<h3 class="wp-block-heading">Departures From Game Pass</h3>
On Nov. 30, several titles will leave the Xbox Game Pass catalog, including fan favorites like Conan Exiles and Remnant: From the Ashes.<a href="https://www.benzinga.com/24/11/42044705/this-six-games-are-leaving-xbox-game-pass-by-months-end"> Here's</a> the full list of departing games.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41985800/gta-5-joins-novembers-playstation-plus-lineup-with-other-fan-favorites">GTA 5 Joins November&#8217;s PlayStation Plus Lineup With Other Fan-Favorites</a></li>
</ul>
Image: Shutterstock

MSFT

Xbox Game Pass Brings Big Titles In Late November, Including Stalker, Microsoft Flight Simulator 2024

Cardiol Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>), a clinical-stage life sciences company, reported results from its Phase II open-label MAvERIC-Pilot study of CardiolRx, a cannabidiol-based therapy for treating symptomatic recurrent pericarditis. Cannabidiol (CBD) is a non-psychoactive compound found in the cannabis plant.
The study, presented at the American Heart Association Scientific Sessions 2024, showed sustained reductions in pericarditis pain and inflammation over 26 weeks.
&#8220;The data reported today show that patients enrolled in MAvERIC-Pilot, despite the severity of their disease, experienced clinically relevant and rapid reductions in both their pericarditis pain and C-reactive protein levels that were maintained throughout the study," stated Dr. S. Allen Luis, co-director of the Pericardial Diseases Clinic and associate professor of Medicine in the Department of Cardiovascular Medicine at the Mayo Clinic. "In addition, results demonstrated a substantial reduction in pericarditis episodes per year as compared to the patients&#8217; historical event rate prior to the study. Importantly, treatment was shown to be safe and well tolerated in a population who presented with significant disease burden. I look forward to further investigation in the upcoming Phase II/III and Phase III clinical trials.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40352070/cannabis-and-heart-attack-paradox-new-study-reveals-better-outcomes-for-weed-users">Cannabis And Heart Attack Paradox: New Study Reveals Better Outcomes For Weed Users</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Study Key Takeaways</h2>
The trial enrolled 27 participants (67% female, average age 53) at eight U.S. clinical sites. Patients, with a baseline history of 5.8 episodes per year and significant disease burden, received CardiolRx in addition to existing therapies before transitioning to monotherapy during the study's extension period.
<ul>
<li>Pericardial pain was reduced from 5.8 at baseline to 1.5 at week 26.</li>
<li>Just five days following initiation of CardiolRx, near resolution of pain was observed.</li>
<li>Improvements in inflammation were noted with C-reactive protein (CRP) levels normalizing in 80% of patients by week eight, with sustained improvements throughout the study</li>
<li>At week 8, 93% (25/27) of patients reported a pain score reduction.</li>
<li>CardiolRx was well tolerated, with no significant adverse events reported and a 95% compliance rate.</li>
</ul>
&#8220;The compelling results from MAvERIC-Pilot showed that CardiolRx resulted in marked and rapid reductions in pericarditis pain and inflammation in patients with a high degree of disease burden as well as a striking decrease in pericarditis episodes per year," stated David Elsley, president and CEO of Cardiol Therapeutics. "The notable impact of CardiolRx on these important clinical endpoints demonstrates its potential to offer a more accessible and non-immunosuppressive therapeutic option for tens of thousands of pericarditis patients.&#8221;
Elsley added that these results support advancing the MAVERIC program, which includes the upcoming Phase II/III MAVERIC-1 and Phase III MAVERIC-3 trials.
Cardiol focuses on developing anti-inflammatory and anti-fibrotic therapies for heart diseases. Its lead drug, CardiolRx, leverages cannabidiol's ability to inhibit inflammasome pathways, with applications in pericarditis, myocarditis, and heart failure. The company holds Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis.
<h2 class="wp-block-heading">Price Action</h2>
Cardiol Therapeutics shares closed Monday's market session 1.65% lower at $1.79 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39846088/study-shows-cbd-could-protect-skin-from-sun-damage-by-exposing-participants-to-3x-uv-radiation">Study Shows CBD Could Protect Skin From Sun Damage By Exposing Participants To 3X UV Radiation</a></li>
</ul>
Photo: Courtesy of <a href="https://www.shutterstock.com/g/ARMMY+PICCA">ARMMY PICCA</a> via Shutterstock

Cannabis

CRDL

CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study

NVDA

Nvidia shares are trading higher after multiple analysts raised their price targets on the stock. The company will report Q3 earnings tomorrow.

<a href="https://truthsocial.com/@realDonaldTrump/posts/113511235978420631" title="https://truthsocial.com/@realDonaldTrump/posts/113511235978420631">https://truthsocial.com/@realDonaldTrump/posts/113511235978420631</a>

Macro Economic Events

Politics

Economics

General

President Donald Trump Posts On Truth Social "I Am Thrilled To Announce That Howard Lutnick, Chairman & CEO Of Cantor Fitzgerald, Will Join My Administration As The U.S. Secretary Of Commerce..."

BofA Securities analyst Andrew Obin reiterated the Buy rating on Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), <a target="_blank" href="https://www.benzinga.com/quote/VRT/analyst-ratings" rel="noreferrer noopener">with a price forecast of $150.</a>
Obin writes that, management has revised its organic revenue growth forecast to a 12%-14% CAGR from 2024 to 2029, up from a previous range of 8%-11%.
This compares to BofA and consensus estimates of a 14% CAGR from 2024-2027.
The analyst attributes the revision to potential industry-wide constraints, such as electricity availability and skilled labor shortages.
Vertiv&#8217;s capital expenditure is projected to increase, with capex rising to approximately 3.0% of revenue in 2025, up from 2.6% in 2024, indicating a continued acceleration of capacity expansions.
Also Read<a target="_blank" href="https://www.benzinga.com/news/events/24/11/42069387/grant-cardone-calls-himself-a-coward-investor-puts-his-money-in-real-assets" rel="noreferrer noopener">: Grant Cardone Calls Himself A &#8216;Coward Investor,&#8217; Puts His Money In &#8216;Real Assets&#8217;</a>
As of 3Q24, Vertiv&#8217;s gross equipment assets grew by 25% year-over-year, the analyst writes.
Management also guided for an adjusted operating margin of 25+% by 2029 (or sooner), an improvement from the previous target of 20+% by 2028.
This enhanced margin outlook is despite an increase in R&amp;D and capacity investment, which is now expected to reach $150-200 million per year, up from the previous $75-125 million range, Obin adds.
The analyst raised the 2025 adj. EPS estimate by $0.10 to $3.60 (+33% year over year), driven largely by faster revenue growth.
Obin raised the 2026 adj. EPS estimate by $0.15 to $4.40 (+22% year over year).
The analyst also raised the dividend forecast to reflect the 50% increase to $0.15/share annualized rate in conjunction with the Investor Day.
Price Action: VRT shares are trading higher by 10.9% to $136.49&nbsp;at last check Tuesday.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42046709/raoul-pal-bullish-on-solana-and-memes-dogecoin-does-nothing-does-nothing-and-then-explodes" target="_blank" rel="noreferrer noopener">Raoul Pal Bullish On Solana And Memes: &#8216;Dogecoin Does Nothing, Does Nothing And Then Explodes&#8217;</a></li>
</ul>

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

Movers

Trading Ideas

Vertiv's Earnings Estimates Raised By Analyst Amid Improved Margin Outlook

Investors seem to be throwing in the towel on China very quickly. However, their market has not really fallen back as much as it seems over the past few weeks.
Also, we have to think about what it will mean to President Xi &#8216;s standing on the global stage if he does not come through with a bigger stimulus bazooka blast at some point over the next six months.
One of the narratives on Wall Street that I think is off base is the belief that China &#8216;s economy and markets are headed into the toilet, and that this bearish theme is going to accelerate in the weeks and months ahead. I admit that I&#8217;m not sure what is going to happen over the next few weeks, but I do believe that things will improve through much of 2025, beginning no later than early in the new year.
No, this does not mean that the efforts by Chinese authorities will fix the country&#8217;s long-term structural problems, but I do think their efforts will help improve the situation in China over the intermediate-term.
There is little question that Chinese authorities have not provided the kind of "bazooka blast" of stimulus as quickly as many people thought they would in September, when they first implied that they&#8217;d do whatever it takes to stimulate their economy. However, this does not mean that they won&#8217;t shoot that bazooka in the future. The Chinese, led by President X, have put a lot of political capital on the line with their announcements in September, so if they don&#8217;t follow-through, it&#8217;s going to make them look very weak on the global stage (especially with President Trump about to become President once again).
I am not an expert on geopolitical issues, but I don&#8217;t see President XI allowing the promises he and his government made back in September to be left flapping in the breeze in 2025.
I also want to put things into perspective when it comes to their stock market. After the massive 30% rally that came in just six days, the CSI 300 index is down "only" 6% from its closing high in early October.
Yes, it&#8217;s down more than 10% from its intraday high on October 8th, but the parabolic move that came at the end of that rally lasted for only a few minutes that day, before closing 5% below its intraday highs. In other words, on a closing basis, the CSI 300 has not fallen in a dramatic way and it still stands 25% above its September lows!
As we move forward, I&#8217;ll be watching the late-October lows of 3,800 for the CSI 300. If it can break above its October closing high of 4,256 and thus follow up that "higher-low" with a "higher-high," it&#8217;s going to be very bullish for China&#8217;s stock market on a technical basis. If (I repeat, IF) it is able to break above its 2024 highs at any point in the coming months, it will be extremely bullish for Chinese stocks!
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141303/China-CSI-1024x524.png" alt="" class="wp-image-655813" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141303/China-CSI-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141303/China-CSI-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141303/China-CSI-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141303/China-CSI.png 1179w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
One thing that does concern me, however, is the action in South Korea &#8216;s KOSPI index. As I mentioned last week, the KOSPI index has been hit hard since the US election after already experiencing a rough four months. It is now down over 16%, and it has broken below its summer lows. It is now very close to testing its trend-line going all the way back to the October 2022 lows. So, a break below that level would be quite bearish on a technical basis.
That said, the KOSPI is getting oversold, so it could bounce soon. However, if it breaks below that line in any meaningful way, either now, or after a short-term bounce, it will not be good at all. Since South Korea is such a big exporter, especially to China, a further decline in the KOSPI would not be a good sign at all for China &#8216;s economy.
In other words, I do admit that the problems in China could be too difficult for the authorities to control going forward. Thus, I&#8217;ll be watching the KOSPI index for clues on this front.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="515" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141316/South-Korea-KOSPI-1024x515.png" alt="" class="wp-image-655815" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141316/South-Korea-KOSPI-1024x515.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141316/South-Korea-KOSPI-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141316/South-Korea-KOSPI-768x386.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19141316/South-Korea-KOSPI.png 1154w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
 This week, you can join my Inner Circle for just $199 (regularly $3,000) and get immediate access to the same strategies and trade setups that have helped my members achieve 100%+ gains. <a href="https://www.benzinga.com/premium/ideas/matt-199-offer/?utm_source=WebRD-1119">Click Here to Join!</a>
Image via Shutterstock

Opinion

How You'll Know That Chinese Stocks Are About To Take Off

Trulieve Cannabis Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>, CSE:<a class="ticker" href="https://www.benzinga.com/stock/TRUL#CSE">TRUL</a>) executives recently purchased 26,000 shares, signaling potential confidence in the company's future. Between November 8 and 13, COO Marie Zhang, CPO Kyle Landrum, and CLO Eric Powers increased their holdings, according to a report by Beacon Securities. 
Zhang made the largest move, acquiring 21,300 shares at an average price of $7.19, adding $153,147 of an estimated total of around $186.000. What does this mean for investors? Is the stock undervalued?
<h3 class="wp-block-heading">Stock Decline</h3>
Trulieve's stock has dropped sharply in recent weeks, trading at around $6.34 after peaking at $14 in mid-October. The decline follows two major setbacks: the failure of Florida's cannabis legalization ballot and heightened political uncertainty tied to Donald Trump's election victory.
These setbacks created an election gapt hat the stock has yet to close.
There&#8217;s a reason why those events had a significant impact on the company. <a href="https://www.benzinga.com/topic/florida-cannabis">Florida</a> is the company's largest market, and the <a href="https://www.benzinga.com/markets/cannabis/24/11/41780079/floridas-cannabis-initiative-defeated-trulieve-ceo-kim-rivers-nfls-ricky-williams-and-others-res">ballot's failure</a> denied an opportunity to double the size of the state's legal cannabis market. A Trump presidency also <a href="https://www.benzinga.com/general/market-summary/24/11/42049450/can-trumps-return-save-the-cannabis-sector-debt-mounts-as-giants-face-post-election-reckoning">raises concerns</a> about the future of federal cannabis reform, further complicating Trulieve's growth outlook.
The ballot's defeat was particularly damaging. If approved, it would have allowed Trulieve to expand its 156 Florida stores into the recreational market, dramatically boosting revenue potential.
Adding to these challenges, Trulieve's third-quarter 2024 earnings showed <a href="https://www.benzinga.com/markets/cannabis/24/11/41743807/trulieves-q3-revenue-up-slightly-year-over-year-net-loss-grows-amid-48m-in-cannabis-legalization">mixed results</a>. The company reported $284 million in revenue, a modest 3% increase from the previous year, with a strong gross margin of 61% and adjusted EBITDA of $96 million (up 24% year-over-year). However, a $60 million net loss, significantly higher than the $25.4 million loss in Q3 2023 highlighted the financial strain of $48 million in non-recurring expenses tied to the Florida ballot campaign.
Read Also: <a href="https://www.benzinga.com/general/market-summary/24/11/42049450/can-trumps-return-save-the-cannabis-sector-debt-mounts-as-giants-face-post-election-reckoning">Can Trump&#8217;s Return Save The Cannabis Sector? Debt Mounts As Giants Face Post-Election Reckoning</a>
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Is Trulieve Undervalued?</h3>
<a href="https://www.benzinga.com/markets/cannabis/22/05/27419808/trulieve-executives-buying-their-company-shares-heres-what-we-know">Insider stock purchases</a> often indicate that management views the stock as undervalued. These moves could also be intended to restore investor confidence after a significant drop. However, determining undervaluation is complex and subjective, often requiring a mix of financial analyses and market sentiment.
From a technical perspective, Trulieve appears oversold, with an RSI of 31.94, suggesting the possibility of a rebound. Key resistance levels are $9.58 (SMA) and $14 (the October high), while support hovers at $6.00, with a critical floor near $3.71 (lower Bollinger Band). Recent high volumes during the selloff suggest heavy selling pressure, but the current lower volumes indicate stabilization. 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="630" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19123625/Captura-de-pantalla-2024-11-19-a-las-14.36.18-1024x630.png" alt="" class="wp-image-655536" style="width:613px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19123625/Captura-de-pantalla-2024-11-19-a-las-14.36.18-1024x630.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19123625/Captura-de-pantalla-2024-11-19-a-las-14.36.18-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19123625/Captura-de-pantalla-2024-11-19-a-las-14.36.18-768x473.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/19123625/Captura-de-pantalla-2024-11-19-a-las-14.36.18.png 1071w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Chart <a href="https://pro.benzinga.com/dashboard">created using Benzinga Pro</a>
At a glance, it seems the market has not bought yet on the promising future this cannabis company has to offer, with or without legal recreational cannabis in Florida. But, with small-cap cannabis stocks prone to volatility, this is a situation investors should monitor closely.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/11/41743807/trulieves-q3-revenue-up-slightly-year-over-year-net-loss-grows-amid-48m-in-cannabis-legalization">Trulieve&#8217;s Q3 Revenue Up Slightly Year-Over-Year, Net Loss Grows Amid $48M In Cannabis Legalization Support</a></li>
</ul>
Cover: AI generated image

Buybacks

CSE:TRUL

TCNNF

Trulieve Cannabis Execs Buy 26K Company Shares: What Does This Mean For Investors?

<a href="https://www.benzinga.com/digital-assets/livestream" title="https://www.benzinga.com/digital-assets/livestream">https://www.benzinga.com/digital-assets/livestream</a>

Benzinga's Future Of Digital Assets Panel 'The Promises and Complexity of Internet Breakthroughs' Begins

Alzamend Neuro (ALZN) has provided an update. On July 12, 2024, the Company announced a Reverse Stock Split, highlighting that this move is not an ...

Alzamend Neuro Announces Reverse Stock Split Decision

Alzamend Neuro (ALZN) just unveiled an update. Alzamend Neuro, Inc. successfully regained compliance with Nasdaq's Minimum Bid Price Requirement af...

Alzamend Neuro Meets Nasdaq Standards, Embraces Social Media

Warning: ALZN is at high risk of performing badly

Alzamend Neuro regains compliance with Nasdaq

Alzamend Neuro ( ($ALZN) ) has issued an announcement. Alzamend Neuro, a biopharmaceutical company targeting Alzheimer's and other disorders, succe...

Alzamend Neuro Regains Nasdaq Compliance After Strategic Appeal

ALZN

Press Releases

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Alzamend Neuro Issues Letter to Stockholders

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group's Virtual Healthcare Conference

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice

Comments

Alzamend Neuro

Intérêt court

Alzamend Neuro (NASDAQ:ALZN) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL